DOCSLIB.ORG

Value Creation Throug M&A : a Clinical Study on Blockbuster Deal Evidence

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Value Creation Throug M&A : a Clinical Study on Blockbuster Deal Evidence VALUE CREATION THROUG M&A : A CLINICAL STUDY ON BLOCKBUSTER DEAL EVIDENCE IN THE PHARMACEUTICAL INDUSTRY __________________________________________________ LES ETUDES DU CLUB N° 102 DECEMBRE 2013 VALUE CREATION THROUG M&A : A CLINICAL STUDY ON BLOCKBUSTER DEAL EVIDENCE IN THE PHARMACEUTICAL INDUSTRY __________________________________________________ LES ETUDES DU CLUB N° 102 DECEMBRE 2013 Etude réalisée par Mademoiselle Rose Le Moullac (MSc in International Finance 2013) sous la direction de Monsieur Nicolas Naillon Professeur Vacataire à HEC PARIS Table of Contents GENERAL INTRODUCTION ........................................................................................................... 4 PART I: OVERVIEW OF THEORY AND ACADEMIC LITERATURE ............................... 7 Chapter 1: Theoretical overview of value creation ................................................................................... 7 1. Definition ........................................................................................................................................................................ 7 2. Measurement .................................................................................................................................................................. 9 2.1 Measures for the specific assessment of value creation in the context of M&A ............................................ 10 2.1.1. Synergies ...................................................................................................................................................................... 10 2.1.2. Event studies ............................................................................................................................................................... 13 2.2 Assessment methods applicable to both standalone or merged firms: value creation indicators .............. 16 2.2.1. Financial indicators ................................................................................................................................................... 17 2.2.1.1. Net present value (NPV) ................................................................................................................................ 17 2.2.2. Accounting/financial indicators (hybrid measures) ....................................................................................... 18 2.2.2.1. ROCE – WACC ................................................................................................................................................ 18 2.2.2.2. Economic Value Added (EVA) ................................................................................................................... 18 2.2.3. Accounting indicators .............................................................................................................................................. 19 2.2.3.1. Profit measures: Net profit and EPS .......................................................................................................... 20 2.2.3.2. Profitability measures: ROE and ROCE .................................................................................................. 20 2.2.3.3. Summary of advantages and drawbacks ................................................................................................... 21 2.2.4. Market indicators ....................................................................................................................................................... 22 2.2.5. Value drivers/key performance indicators (KPIs) .......................................................................................... 24 Chapter 2: Review of existing literature on value creation ................................................................... 25 1. In general ..................................................................................................................................................................... 25 1.1. Event studies ......................................................................................................................................................................... 25 1.2. Accounting studies .............................................................................................................................................................. 28 1.3. Other studies ......................................................................................................................................................................... 31 2. In the pharmaceutical industry .............................................................................................................................. 31 2.1. Event studies ......................................................................................................................................................................... 31 2.2. Case study .............................................................................................................................................................................. 34 PART II: CASE STUDY .................................................................................................................... 38 Chapter 1: Case study presentation ........................................................................................................... 38 1. Sample selection ........................................................................................................................................................ 38 1.1. Case study sample ............................................................................................................................................................... 38 1.2. Benchmark sample .............................................................................................................................................................. 40 2. Background ................................................................................................................................................................. 41 2.1. Company descriptions ....................................................................................................................................................... 41 2.1.1. Pfizer .............................................................................................................................................................................. 41 2.1.2. Wyeth ............................................................................................................................................................................. 43 2.2. Industrial and economic context .................................................................................................................................... 44 2.2.1. General dynamics of the pharmaceutical industry .......................................................................................... 44 2.2.2. The pharmaceutical industry in the 2000s ......................................................................................................... 46 2.2.2.1. R&D cost and productivity challenges ..................................................................................................... 47 2.2.2.2. Impending patent cliffs ................................................................................................................................... 49 2.2.2.3. Price pressure ..................................................................................................................................................... 50 2.2.2.4. Pressure from capital markets ...................................................................................................................... 51 2.2.2.5. General economic context ............................................................................................................................. 51 2.2.2.6. Conclusion .......................................................................................................................................................... 51 2.3. Company specific concerns ............................................................................................................................................. 52 Chapter 2: Presentation and discussion of findings ................................................................................ 54 1. Transaction overview ............................................................................................................................................... 54 Rose Le Moullac 2 MIF Thesis 1.1. Transaction description ..................................................................................................................................................... 54 1.2. Transaction rationale .......................................................................................................................................................... 56 1.3. Expected synergies ............................................................................................................................................................. 58 2. Assessment of value creation ................................................................................................................................ 60 2.1. Qualitative assessment ....................................................................................................................................................... 60 2.1.1. Reactions ....................................................................................................................................................................
Load more

Recommended publications
  • The Drug Repurposing Ecosystem: Intellectual Property Incentives
    Halabi: The Drug Repurposing Ecosystem: Intellectual Property Incentives, The Drug Repurposing Ecosystem: Intellectual Property Incentives, Market Exclusivity, and the Future of "New" Medicines Sam F. Halabil 20 YALE J. L. & TECH. 1 (2018) The pharmaceutical industry is in a state of fundamental transition.New drug approvals have slowed, patents on blockbuster drugs are expiring, and costs associated with developing new drugs are escalating and yielding fewer viable drug candidates. As a result, pharmaceutical firms have turned to a number of alternative strategies for growth. One of these strategies is "drug rep urposing"-findingnew ways to deploy approved drugs or abandoned clinical candidates in new disease areas. Despite the efficiency advantages of repurposing drugs, there is broad agreement that there is insufficient repurposing activity because of numerous intellectual property protection and market failures. This Article examines the system that surrounds drug repurposing, including serendipitous discovery, the application of "big data" methods to prioritize promising repurposing candidates, the unorthodoxly regulated off-label prescription practices of providers, and related prohibitions on pharmaceutical firms' off-label marketing. The Article argues that there is a complex ecosystem in place and that additional or disruptive IP Fulbright Canada Research Chair in Health Law, Policy, and Ethics, University of Ottawa and Associate Professor, University of Missouri School of Law.; J.D. Harvard; M.Phil. The University of Oxford (St. Antony's College); B.A., B.S. Kansas State University. The author is grateful for comments and helpful suggestions given at faculty workshops at Arizona State University's Sandra Day O'Connor School of Law, Boston University's biolP Faculty Workshop, and Seton Hall University School of Law, as well as the American Society of Law, Medicine, and Ethics' Annual Health Law Professors Conference.
    [Show full text]
  • Vallenar Bay Article – Ketchikan Daily News
    Mariners get 1st win Mom organizes Houghtaling safety • Seattle takes it to Texas, committee, See page 7 Page 16 48 º/39 º Weather, page 3 $K1.00 ETCHIKAN WEDNESDAY, APRIL 6, 2016 T WDITTER.COAM/KDNI NEWLS Y N WWW.KEETCHIWKANDAILYNSEWS.COM 16 PAGES Gravina Prince of Wales tells whale tales Local pot road plan panel out to bid returning By MATT ARMSTRONG Daily News Staff Writer By NICK BOWMAN The State of Alaska put a Gravina Is - Daily News Staff Writer land road project out to bid on Thurs - A clash between state marijuana day. law and federal control of air and The state’s Department of Natural water transportation is resurrecting Resources issued an invitation to bid Ketchikan’s Marijuana Advisory Com - on construction of new roads and re - mittee. construction of existing roads as part of The committee of local leaders from the Division of Forestry’s proposed Val - the Ketchikan Gateway Borough As - lenar Bay Timber Sale. sembly, Ketchikan and Saxman city The bid is “for the construction of 8.4 councils and the Ketchikan School miles of linear graded road and associ - Board guided marijuana policy on the ated drainage structures, supply and in - island in 2015, but has been dormant stall of culverts and modular bridges as for months after approving a set of necessary, reconstruction of approxi - final recommendations. mately 1.1 miles of existing forest road However, the committee will meet and associated drainage structures.” again to discuss whether local policy According to the bid invitation, the should change as a result of federal state-funded road project has an esti - control of air and water travel.
    [Show full text]
  • Classnotes: Fall 2019 Written by Kmerusi
    DREW CLASSNOTES The College of Liberal Arts Ronald Vander Schaaf C’56, T’59 One of the most fit men in our class has September I went to Sloss Furnace, a defunct 56 [email protected] got to be Roy Haynes. He entered a 5K race steel mill, to see the dedication of a plaque Prunella (Read) Williams, Harold in Wooster, Ohio, and finished it! He finished that honors two men, Tom Redmond and “Hal” Quigley and Barbara (Young) Quigley third of the six men who were in the age-70- Jake McKenzie, who were lynched on Sloss visited Flora (Robinson) Hullstrung in and-over group. For that he received a $10 property in 1890 and 1897. In a “small August this past summer. All are doing well. gift certificate. Ruth (Schubert) Haynes world” moment, the man next to me and The late Bob Hullstrung’s cousin Garrett didn’t enter the race, but she is enjoying the I began the normal kind of conversation visited Flora for four days as well. Garrett new storage areas added to their kitchen. between two strangers. When it got around lives on Maui, Hawaii. Lynn (Swader) Monk Mary (Henck) Sharp modestly reported to children, he mentioned that his daughter Fedor is planning to move to a smaller that she and Richard have visited all 50 went to a small college in New Jersey. It facility. In the process of getting ready for states and seven continents. In August, they turned out to be Drew! And she was there! the move, she discovered her file of past went on a two-week truck tour of Russia.
    [Show full text]
  • Steve Brozak Interview with the Life Sciences Report 5-27-15
    As Cancer Immunotherapy Turns 125, WBB Securities' Steve Brozak Ponders What Investors Can Expect from Biotech Next The Life Sciences Report www.TheLifeSciencesReport.com 05/27/2015 Steve Brozak sees a bubble getting larger, and he is anticipating the time COMPANIES MENTIONED when biotech stocks pull back to take a breather, like all high-flying markets Bellicum Pharmaceuticals Inc. ultimately do. While investors may own innovative companies with highly bluebird bio Inc. disruptive technologies, Brozak insists on careful diligence to find names with the potential for explosive growth and avoid the disappearing acts. In this Celldex Therapeutics Inc. interview with The Life Sciences Report, Brozak, president and managing Juno Therapeutics partner at WBB Securities, showcases six names with strong Kite Pharma immunotherapeutic platforms that he believes have extraordinary potential to Navidea Biopharmaceuticals Inc. reward investors many times over. Source: George S. Mack of The Life Sciences Report The Life Sciences Report: Steve, I know that you believe we're in a biotech Streetwise Reports LLC bubble right now. The NYSE.Arca Biotechnology Index (BTK) is up 33% over the 101 Second St., Suite 110 past year, and 132% over the past two years. The NASDAQ Biotechnology Index Petaluma, CA 94952 (NBI) is up 57% and 99% during those corresponding periods. Biotech has Tel.: (707) 981-8107 performed quite well. Why do you think we're headed for trouble? Fax: (707) 981-8998 [email protected] Steve Brozak: The problem I have with looking at these new therapeutic modalities as investments is that they don't lend themselves to general biotech stock and index THE ENERGY REPORT buying.
    [Show full text]
  • Financial Times and Thomson Reuters Name Steve Brozak As a 2013 Starmine "Top Stock Picker"
    Financial Times and Thomson Reuters name Steve Brozak as a 2013 StarMine "Top Stock Picker" WBB's Steve Brozak named "Top Stock Picker" in Pharmaceuticals For Immediate Release August 22, 2013 SAN DIEGO, CA – The Financial Times and Thomson Reuters have named Steve Brozak, president of WBB Securities as a 2013 StarMine "top stock picker" among Pharmaceutical Analysts. With this award, Brozak has achieved top-ranking recognition in all healthcare fields including Biotechnology, Medical Devices, and Pharmaceuticals over the last four years by the Thomson Reuters Awards for Excellence or The Wall Street Journal Best on the Street Survey. Each year, the StarMine Analyst Awards recognize analysts who have shown exemplary performance either as stock pickers or as earnings estimators during the prior year. The 2013 stock picking awards for the United States are based on the 2012 calendar-year performance of recommendations. Only analyst performance on companies that are based in the United States are included in the awards calculations. WBB Securities is often quoted in news media and has contributed opinion articles on a wide range of healthcare and economic issues. Steve Brozak is a guest contributor to Forbes.com, ABCNews.com and Bloomberg.com, frequently publishing opinion articles in those publications. About WBB Securities WBB Securities is a leading investment management, investment banking, and equity research firm. Established in 2001 and headquartered in San Diego, California, WBB Securities is a registered independent broker dealer and investment advisor with proprietary trading desks that have market-making capabilities. WBB Securities has built a nationwide team of respected senior investment and research professionals with a network of branches throughout the US serving institutional and high net worth clients.
    [Show full text]
  • Annals of Health Law
    BEAZLEY INSTITUTE FOR HEALTH LAW AND POLICY Annals OF Health Law ADVANCE DIRECTIVE The Online Health Policy and Law Review of Loyola University Chicago School of Law BRINGING YOU THE LATEST DEVELOPMENTS IN HEALTH LAW Volume 18 | Online Issue 2 SPRING 2009 ANNALS OF HEALTH LAW ADVANCE DIRECTIVE THE ONLINE HEALTH POLICY AND LAW REVIEW OF LOYOLA UNIVERSITY CHICAGO SCHOOL OF LAW BRINGING YOU THE LATEST DEVELOPMENTS IN HEALTH LAW Beazley Institute for Health Law and Policy VOLUME 18, ONLINE ISSUE 2 SPRING 2009 CONTENTS Editor’s Note Ann Weilbaecher, Editor-in-Chief......................................i PART I: WINNER OF THE 2008 ILLINOIS ASSOCIATION OF HEALTHCARE ATTORNEYS’ STUDENT WRITING CONTEST No-Fault Solutions to the Problem of Medical Injuries: A Focus on Sweden as a Model Sarah Hoffman...................................................73 PART 2: LAW AND PUBLIC HEALTH ARTICLES Health Care in a Time of Financial Crisis: Is the Economic Downturn a Sufficient Excuse to Delay Health Reform Once Again? Kristin Savov.....................................................94 ARTICLES (CONTINUED) Medical Tourism: An Informed Choice May Present A Safe And Realistic Alternative To Expensive Treatment At Home Adrienne Sevilla ................................................103 Autism Insurance Coverage: Is the Cost of a National Mandate Too Burdensomein an Uncertain Economy? Rebecca L. Segal.................................................111 Vaccinations and Public Health: For the Greater Good Sherri DeVito ...................................................117 Ethnic Disparities in Influenza Immunization Rates Susie Shin…………..........................................125 Good Importer Practices: Can the FDA Afford to Rely on the Importer for Food Safety? Christy O’Berry..................................................133 Patent Pools for Orphan Diseases Jeffrey D. Shelley................................................141 Access to Mental Health Services for Juvenile Detainees Colleen Burns...................................................150 Altria Group, Inc.
    [Show full text]
  • Local Delegates Prepare for DEM Nat'l Convention
    Ad Populos, Non Aditus, Pervenimus (908) 232-4407 USPS 680020 Thursday, July 22, 2004 Published Every Thursday Since 1890 OUR 114th YEAR – ISSUE NO. 46-114 Periodical – Postage Paid at Westfield, N.J. www.goleader.com [email protected] SIXTY CENTS Local Delegates Prepare For DEM Nat’l Convention By HORACE R. CORBIN and that.” John Kerry in Boston - a time when MICHAEL POLLACK Assemblywoman Stender has been Specially Written for The Westfield Leader Kerry was fighting for his political life chosen as a delegate to the convention in running for reelection as Senator for Several of the area’s community based on her strength as an elected Massachusetts. Mr. Regenstreich said leaders and party advocates are gear- official for the 22nd Legislative Dis- to Kerry, “if there’s anything I can do ing up to serve as delegates to the trict in New Jersey. Asw. Stender told for you, please give me a call.” The next Democratic National Convention The Leader/Times that “I am proud to day when he returned home to NJ, there (DNC) in Boston next week, July 26 participate in our American democracy were two messages on his answering to 29. They will officially confirm as a delegate to the Democratic Na- machine. He was living in Montclair at their party’s nominees of Sena- the time, before he and his wife tor John Kerry (D-MA) for Presi- Merry moved to Westfield six years dent and Senator John Edwards ago. (D-NC) for Vice President of the He told The Leader/Times that United States.
    [Show full text]
  • THE DRUG REPURPOSING ECOSYSTEM: INTELLECTUAL PROPERTY INCENTIVES, MARKET EXCLUSIVITY, and the FUTURE of “NEW” MEDICINES Sam F
    THE DRUG REPURPOSING ECOSYSTEM: INTELLECTUAL PROPERTY INCENTIVES, MARKET EXCLUSIVITY, AND THE FUTURE OF “NEW” MEDICINES Sam F. Halabi | Yale Journal of Law and Technology Document Details All Citations: 20 Yale J. L. & Tech. 1 Search Details Jurisdiction: National Delivery Details Date: March 4, 2018 at 8:47 PM Delivered By: kiip kiip Client ID: KIIPLIB02 Status Icons: © 2018 Thomson Reuters. No claim to original U.S. Government Works. THE DRUG REPURPOSING ECOSYSTEM: INTELLECTUAL..., 20 Yale J. L. & Tech. 1 20 Yale J. L. & Tech. 1 Yale Journal of Law and Technology 2018 Sam F. Halabi 1 Copyright © 2018 Yale Journal of Law & Technology, Sam F. Halabi THE DRUG REPURPOSING ECOSYSTEM: INTELLECTUAL PROPERTY INCENTIVES, MARKET EXCLUSIVITY, AND THE FUTURE OF “NEW” MEDICINES The pharmaceutical industry is in a state of fundamental transition. New drug approvals have slowed, patents on blockbuster drugs are expiring, and costs associated with developing new drugs are escalating and yielding fewer viable drug candidates. As a result, pharmaceutical firms have turned to a number of alternative strategies for growth. One of these strategies is “drug repurposing”--finding new ways to deploy approved drugs or abandoned clinical candidates in new disease areas. Despite the efficiency advantages of repurposing drugs, there is broad agreement that there is insufficient repurposing activity because of numerous intellectual property protection and market failures. This Article examines the system that surrounds drug repurposing, including serendipitous discovery, the application of “big data” methods to prioritize promising repurposing candidates, the unorthodoxly regulated off-label prescription practices of providers, and related prohibitions on pharmaceutical firms' off-label marketing.
    [Show full text]
  • The Drug Repurposing Ecosystem: Intellectual Property Incentives, Market Exclusivity, and the Future of “New” Medicines
    The Drug Repurposing Ecosystem: Intellectual Property Incentives, Market Exclusivity, and the Future of “New” Medicines Sam F. Halabi1 20 YALE J. L. & TECH. 1 (2018) The pharmaceutical industry is in a state of fundamental transition. New drug approvals have slowed, patents on blockbuster drugs are expiring, and costs associated with developing new drugs are escalating and yielding fewer viable drug candidates. As a result, pharmaceutical firms have turned to a number of alternative strategies for growth. One of these strategies is “drug repurposing”—finding new ways to deploy approved drugs or abandoned clinical candidates in new disease areas. Despite the efficiency advantages of repurposing drugs, there is broad agreement that there is insufficient repurposing activity because of numerous intellectual property protection and market failures. This Article examines the system that surrounds drug repurposing, including serendipitous discovery, the application of “big data” methods to prioritize promising repurposing candidates, the unorthodoxly regulated off-label prescription practices of providers, and related prohibitions on pharmaceutical firms’ off-label marketing. The Article argues that there is a complex ecosystem in place and that additional or disruptive IP 1 Fulbright Canada Research Chair in Health Law, Policy, and Ethics, University of Ottawa and Associate Professor, University of Missouri School of Law.; J.D. Harvard; M.Phil. The University of Oxford (St. Antony’s College); B.A., B.S. Kansas State University. The author is grateful for comments and helpful suggestions given at faculty workshops at Arizona State University’s Sandra Day O’Connor School of Law, Boston University’s bioIP Faculty Workshop, and Seton Hall University School of Law, as well as the American Society of Law, Medicine, and Ethics’ Annual Health Law Professors Conference.
    [Show full text]
  • 3Rd Annual Sachs Cancer
    WELCOME SPEAKERS 3rd Annual Sachs Cancer Bio Partnering & PRESENTING COMPANIES Investment Forum Promoting Public & Private Sector, Collaboration & Investment in Drug Development SUPPORTING ORGANISATIONS SUPPORTING 23rd February 2015 New York Academy of Sciences • USA Conference Guide ORGANISERS www.sachsforum.com 3RD ANNUAL SACHS CANCER BIO PARTNERING & INVESTMENT FORUM BIO PARTNERING 3RD ANNUAL SACHS CANCER 3rd ANNUAL t WELCOME Cancer Bio Partnering & Investment Forum back :: next u Sachs Associates are delighted to welcome you to the: 3rd Annual Sachs Cancer SPEAKERS Bio Partnering & Investment Forum Promoting Public & Private Sector, Collaboration & Investment in Drug Development 23rd February 2015 • New York Academy of Sciences • USA PRESENTING COMPANIES Sachs Associates, building upon it’s many years of expertise in organizing premier partnering and investor meetings in Europe and the United States, is proud to welcome you to the 3rd Annual Sachs Cancer Bio Partnering & Investment Forum being held on 23rd February 2015 at the New York Academy of Sciences. This forum is designed to bring together thought leaders from cancer research institutes, patient advocacy groups, pharma and biotech to facilitate partnering and funding/investment. Sachs Associates would like to thank our sponsors and partners who have helped make this event possible. ORGANISATIONS SUPPORTING General Information • The registration desk is open from 8.00am on 23rd February although you are welcome to join the event at any time. Please collect a copy of the agenda for information on timing and room allocation for each session. • One-to-one meetings Please bring with you a copy of your diary. Should you have any queries about your schedule, the laptop situated by the meeting tables is available for your assistance.
    [Show full text]